Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Oncology | Gastroenterology | Endocrinology | Family Medicine
Pancreatic Cancer Clinical Trials
A listing of Pancreatic Cancer medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Birmingham : University of Alabama Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Mobile : University of South Alabama Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Muscle Shoals : Northwest Alabama Cancer Center
Safety and Exploratory Efficacy of Kanglaite Injection in Pancreatic Cancer
Arizona
Tucson : Arizona Cancer Center Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Arkansas
California
Duarte : City of Hope Updated
A Phase III Study of Chemotherapy and Chemoradiotherapy With or Without HyperAcute®-Pancreas (algenpantucel-L) immunotherapy in Subjects with Surgically Resected Pancreatic Cancer
Duarte : City of Hope Updated
SWOG S1115: Randomized Phase II Clinical Trial of AZD6244 Hydrogen Sulfate (NSC-748727) and MK-2206 (NSC-749607) vs mFOLFOX in Patients with Metastatic Pancreatic Cancer After Prior Chemotherapy
View More »
Los Angeles : Cedars-Sinai Medical Center Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Palo Alto : Stanford Cancer Center Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Sacramento : Sutter Institute for Medical Research Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
San Francisco : California Pacific Medical Center Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Colorado
Aurora : University of Colorado Denver
Gemcitabine/Capecitabine/ZD6474 in Advanced Solid Tumors
Aurora : University of Colorado Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Connecticut
Stamford : Stamford Hospital Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Delaware
Newark : Helen F. Graham Cancer Center
Ph I Dose Escalation Study of Antibody-drug Conjugate IMMU-132 in Patients With Advanced Epithelial Cancers
District of Columbia
Florida
Boca Raton : Boca Raton Hospital Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Fort Lauderdale : Broward Oncology Associates
Safety and Exploratory Efficacy of Kanglaite Injection in Pancreatic Cancer
Gainesville : University of Florida Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Jacksonville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer
Jacksonville : Mayo Clinic Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
View More »
Jacksonville : Baptist Cancer Institute
Safety and Exploratory Efficacy of Kanglaite Injection in Pancreatic Cancer
Lakeland : Lakeland Regional Cancer Center Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Miami : University of Miami Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Miami : University of Miami
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
New Port Richey : Pasco Pinellas Cancer Center
Safety and Exploratory Efficacy of Kanglaite Injection in Pancreatic Cancer
Sarasota : Florida Cancer Specialists
Safety and Tolerability Study in Solid Tumors
Tampa : MOFFITT Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Tampa : USF Tampa General Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Tampa : H. Lee Moffitt Cancer Center and Research Institute
Phase II Trial Evaluating OS With Therasphere® + 2nd-Line FOLFOX in Pancreatic Liver Mets
Georgia
Savannah : Memorial University Medical Center Updated
ACOSOG Z5041 : A Phase II Study of Preoperative Gemcitabine and Erlotinib Plus Pancreatectomy and Postoperative Gemcitabine and Erlotinib for Patients with Operable Pancreatic Adenocarcinoma.
Savannah : Memorial University Medical Center Updated
RTOG 0848: A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma.
Illinois
Indiana
Goshen : IU Health Goshen Cancer Center
Ph I Dose Escalation Study of Antibody-drug Conjugate IMMU-132 in Patients With Advanced Epithelial Cancers
Indianapolis : Investigative Clinical Research of Indiana, LLC Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Indianapolis : Indiana University Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Iowa
Ames : McFarland Clinic
Safety and Exploratory Efficacy of Kanglaite Injection in Pancreatic Cancer
Iowa City : University of Iowa Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Kansas
Westwood : University of Kansas Cancer Center Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Kentucky
Louisville : University of Louisville Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Louisiana
Baton Rouge : Mary Bird Perkins Cancer Center Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Baton Rouge : Mary Bird Perkins Cancer Center
Safety and Exploratory Efficacy of Kanglaite Injection in Pancreatic Cancer
New Orleans : Ochsner Cancer Institute Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Maryland
Baltimore : University of Maryland Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Massachusetts
Boston : Massachusetts General Hospital Dept. of Mass General Hospital
Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients
Boston : Massachusetts General Hospital Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Boston : Beth Israel Deaconess Medical Center Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Boston : Dana-Farber Cancer Institute Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Boston : Massachusetts General Hospital Cancer Center
Safety Study of MGA271 in Refractory Cancer
View More »
Burlington : Lahey Clinic Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Michigan
Minnesota
Missouri
Nebraska
Lincoln : Southeast Nebraska Hematology & Oncology Consultants
Safety and Exploratory Efficacy of Kanglaite Injection in Pancreatic Cancer
Omaha : University of Nebraska Medical Center Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
New Jersey
Jersey City : CarePoint Health Research Institute Updated
Conducting Pancreatic Cancer Clinical Research for the Future
New Mexico
Albuquerque : University of New Mexico Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
New York
Bronx : Einstein-Montefiore Institute for Clinical & Translational Research
A Phase 2 Study of REOLYSIN in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma
Bronx : Biomedical Research Alliance of New York
Pancreatic Cancer - Adults
View More »
Lake Success : Arena Oncology Associates
Safety and Exploratory Efficacy of Kanglaite Injection in Pancreatic Cancer
New York : Memorial Sloan Kettering Cancer Center MSKCC - SC
Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients
New York : Mount Sinai Medical Center Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
New York : Weill Cornell/New York Presbyterian Hospital
Ph I Dose Escalation Study of Antibody-drug Conjugate IMMU-132 in Patients With Advanced Epithelial Cancers
New York : Memorial Sloan Kettering Cancer Center
Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess
Staten Island : Richmond University Medical Center
Safety and Exploratory Efficacy of Kanglaite Injection in Pancreatic Cancer
North Carolina
Durham : Duke University Medical Center Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Winston-Salem : Wake Forest Baptist Health Comprehensive Cancer Center Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Ohio
Cincinnati : University of Cincinnati Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Cleveland : University Hospitals Case Western Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Cleveland : University Hospitals
Safety and Efficacy of Cryoablation for Abdominal Pain Associated With Pancreatic Cancer
Columbus : Ohio State University Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Oklahoma
Oklahoma City : University of Oklahoma Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Oklahoma City : University of Oklahoma
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Oklahoma City : Stephenson Cancer Center
Phase I Trial of 5-Azacitidine Plus Gemcitabine in Patients With Advanced Pancreatic Cancer
Oregon
Portland : Oregon Health and Science University Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Pennsylvania
Bethlehem : St. Luke's Hospital and Health Network Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Dunmore : Hematology and Oncology Associates of NE PA
Safety and Exploratory Efficacy of Kanglaite Injection in Pancreatic Cancer
Philadelphia : Thomas Jefferson University Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Philadelphia : Fox Chase Cancer Center Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Philadelphia : University of Pennsylvania Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
View More »
Philadelphia : Hospital of the University of Pennsylvania/Abramson Cancer Center
Safety Study of MGA271 in Refractory Cancer
Pittsburgh : University of Pittsburg Medical Center Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Rhode Island
Providence : Roger Williams Medical Center Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
South Carolina
Greenville : Cancer Center of the Carolinas Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Tennessee
Memphis : The West Clinic
Safety and Exploratory Efficacy of Kanglaite Injection in Pancreatic Cancer
Nashville : Sarah Cannon Research Institute
Safety and Tolerability Study in Solid Tumors
Nashville : Sarah Cannon Research Institute
Safety Study of MGA271 in Refractory Cancer
Texas
Dallas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
Dallas : University of Texas Southwestern Medical Center Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Garland : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
Houston : UT MD Anderson Cancer Center
Chemoradiation-Induced Nausea and Emesis: Quality of Life
Houston : Baylor College of Medicine Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
View More »
Houston : Ben Taub Hospital Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Houston : The Methodist Hospital Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Houston : UT MD Anderson Cancer Center
MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer
Houston : Oncology Consultants
Safety and Exploratory Efficacy of Kanglaite Injection in Pancreatic Cancer
Lubbock : Joe Arrington Cancer Research and Treatment Center Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
San Antonio : University of Texas Health Sciences Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
The Woodlands : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
Tyler : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
Utah
Salt Lake City : University of Utah / Huntsman Cancer Institute Huntsman UT
Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients
Virginia
Charlottesville : University of Virginia Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Lynchburg : Lynchburg Hematology-Oncology Clinic, Inc. Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Richmond : Virginia Commonwealth University Updated
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Washington
West Virginia
Morgantown : West Virginia University - Clinical Trials Research Unit
ACOSOG-Z5041: Ph2 of Neoadjuvant and Adjuvant Gemcitabine Hydrochloride and Erlotinib Hydrochloride in pts + Resectable Adenocarcinoma of the Pancreas Undergoing Pancreatectomy.
Wisconsin
Australia
Box Hill : Box Hill Hospital
A Study of Gemcitabine Plus OMP-21M18 as 1st-line Treatment in Subjects With Pancreatic Cancer
Camperdown : Royal Prince Alfred Hospital
A Study of Gemcitabine Plus OMP-21M18 as 1st-line Treatment in Subjects With Pancreatic Cancer
Heidelberg : The Austin Hospital
A Study of Gemcitabine Plus OMP-21M18 as 1st-line Treatment in Subjects With Pancreatic Cancer
Austria
Graz : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Innsbruck : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
St Poelten : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Vöcklabruck : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Wels : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
View More »
Wien : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Wien :
ATX Study:A Study of Avastin (Bevacizumab), Tarceva (Erlotinib) and Xeloda (Capecitabine) in Patients With Locally Advanced and/or Metastatic Pancreatic Cancer
Belgium
Aalst : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Bonheiden : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Brasschaat : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Brugge : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Brussels : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
View More »
Edegem : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
Eupen : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Gilly : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Leuven : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
Liège : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
Liège : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
Mechelen : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Namur : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Oostende : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Sint-Niklaas : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Verviers : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Canada
China
Beijing : Beijing Cancer Hospital
SOX Sequential S-1 in Advanced Biliary Tract Carcinoma（BTC）and Pancreatic Cancer
Shanghai : Shanghai Changhai Hospital
Study With M2ES and Gemcitabine for Patients With Advanced Pancreatic Cancer
Tianjin : Tianjin Medical University Cancer Institute and Hospital
Study of M2ES in Patients With Advanced Pancreatic Cancer After Gemcitabine Treatment Failure
Cyprus
Nicosia : Cyprus Oncology Centre
A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer
France
Aix en Provence : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Aix en Provence cedex 01 : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Amiens : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Bayonne : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Besançon Cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
View More »
Bordeaux : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Boulogne sur Mer Cédex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Bourg en Bresse : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Brive la Gaillarde : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Clermont Ferrand : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Clermont-Ferrand : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
Colmar Cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Dijon : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
La Seyne Sur Mer : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Le Mans Cedex 9 : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Lomme : Hôpital Saint-Philibert
Clinical Evaluation Of Needle-based Confocal Laser Endomicroscopy in The Lymph Nodes Along With Masses and Cystic Tumors of the Pancreas
Longjumeau cedex 1 : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Lyon : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
Lyon : Hôpital Jean Mermoz
Clinical Evaluation Of Needle-based Confocal Laser Endomicroscopy in The Lymph Nodes Along With Masses and Cystic Tumors of the Pancreas
Marseille : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
Marseille : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Marseille : Institut Paoli Calmettes
Clinical Evaluation Of Needle-based Confocal Laser Endomicroscopy in The Lymph Nodes Along With Masses and Cystic Tumors of the Pancreas
Mont de Marsan : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Nancy : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Périgueux cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Paris Cedex 20 : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Pontoise Cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Pringy Cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Reims : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Reims Cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Rennes : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Rouen : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Saint Grégoire cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Saint Quentin : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Soissons Cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Soyaux : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Strasbourg : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Vichy cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Villefranche Sur Saone Cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Villejuif Cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Germany
Augsburg : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Berlin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
Berlin : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Bremerhaven : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Frankfurt : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
View More »
Friedrichshafen : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
Goslar : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Halle/Saale : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Köln : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Kassel : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Koeln :
An Observational Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Leipzig : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
Mannheim : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Marburg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
Mönchengladbach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
Munich : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
Neunkirchen : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Reutlingen : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
Stralsund : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Würselen : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Greece
Athens : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Chania : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Marousi : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Papagou : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Thessaloniki : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Ireland
Dublin : St Vicents University Hospital
A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer
Dublin : Adelaide, Meath & National Childrens Hospital,
A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer
Israel
Jerusalem : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
Kfar Saba : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
Petah Tiqva : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
Tel Hashomer : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
Tel-Aviv : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
Italy
Cefalù PA : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Confreria : A.O. Santa Croce e Carle, Struttura Complessa di Oncologia Medica
A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer
Monza : Azienda Ospedaliera San Gerardo Struttura Complessa Oncologia Medica
A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer
Napoli : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Novara : AOU Maggiore della Carità
A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer
View More »
Padova : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Roma : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Torino : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Verona : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
Japan
Gifu : Gifu University
Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi
Onomichi : Onomichi General Hospital
Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi
Sapporo : Teine-Keijinkai Hospital
Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi
Tokyo : Research Site Updated
A Japanese Phase 1 Trial of TH-302 in Subjects With Solid Tumors and Pancreatic Cancer
Tokyo : The University of Tokyo
Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi
View More »
Tokyo : Tokyo Medical University
Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi
Tokyo : Toho University
Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi
Ube : Yamaguchi University
Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi
Korea, Republic of
Bucheon : Soon Chun Hyang University School of Medicine
Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi
Cheonan : Soon Chun Hyang University School of Medicine
Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi
Daegu : Catholic University of Daegu School of Medicine
Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi
Goyang-si : NATIONAL CANCER CENTER 323, Ilsan-ro, Ilsandong‐gu,
Pancreatic Enzyme Supplementation in Patients With Unresectable Pancreatic Cancer (PESUP)
Incheon : Inha University School of Medicine
Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi
View More »
Seoul : Gangnam Severance Hospital
Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi
Suwon : Ajou University School of Medicine
Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi
Netherlands
Amstelveen : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Amsterdam : VU University Medical Center
Chemoradiation With Gemcitabine in Combination With Panitumumab for Patients With Locally Advanced Pancreatic Cancer
Dordrecht : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Enschede : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Leiderdorp : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
View More »
Purmerend : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Roosendaal : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Vlissingen : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Zutphen : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
New Zealand
Christchurch : Christchurch Hospital
A Study of Gemcitabine Plus OMP-21M18 as 1st-line Treatment in Subjects With Pancreatic Cancer
Hamilton : Waikato Hospital
A Study of Gemcitabine Plus OMP-21M18 as 1st-line Treatment in Subjects With Pancreatic Cancer
Norway
Poland
Bialystok : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Gdansk : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Koszalin : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Krakow : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Lubin : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
View More »
Olsztyn : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Poznan : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Walbrzych : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Wroclaw : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Romania
Alba Iulia : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Baia-Mare : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Brasov : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Bucharest : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Bucuresti : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
View More »
Cluj-Napoca : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Oradea : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Ramnicu Valcea : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Targu Mures : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Timisoara : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Saudi Arabia
Riyadh : National Guard Health Affairs
Oxaliplatin, Gemcitabine, and Erlotinib Study in Patients With Advanced Chemo-naïve Pancreatic Cancer
Singapore
Outram Road : Singapore General Hospital
32P BioSiliconTM in Addition to Gemcitabine in Pancreatic Cancer
Spain
Alicante : Hospital General de Alicante
A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer
Asturias : Medical Oncology Department, Central University Hospital of Asturias
A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer
Barcelona : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
Madrid : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
Madrid : START Madrid
A Study of Gemcitabine Plus OMP-21M18 as 1st-line Treatment in Subjects With Pancreatic Cancer
View More »
Madrid : Hospital Gregorio Marañon
A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer
Pozuelo De Alarcon : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
Sevilla : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
Valencia : Department of Medical Oncology, Hospital Universitari La Fe,
A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer
Valencia : Instituto Valenciano de Oncologia
A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer
Zaragoza : Hospital Miguel Servet
A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer
United Kingdom
Acton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
Blackburn : Royal Blackburn Hospital
A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer
Bournemouth : The Royal Bournemouth Hospital
Clinical Trial Comparing Gemcitabine and Vandetanib Therapy With Gemcitabine Alone in Pancreatic Carcinoma
Bradford : Bradford Royal Infirmary
A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer
Cambridge : Cambridge University Hospitals NHS Foundation Trust Updated
HYPAZ: Hypertension Induced by Pazopanib
View More »
Cardiff : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
Cardiff : Velindre Cancer Centre
A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer
Dundee : Ninewells Hospital,
A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer
Edinburgh : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
Guildford : Royal Surrey County Hospital
Clinical Trial Comparing Gemcitabine and Vandetanib Therapy With Gemcitabine Alone in Pancreatic Carcinoma
Liverpool : Royal Liverpool University Hospital
Clinical Trial Comparing Gemcitabine and Vandetanib Therapy With Gemcitabine Alone in Pancreatic Carcinoma
Liverpool : Clatterbridge Centre for Oncology
Clinical Trial Comparing Gemcitabine and Vandetanib Therapy With Gemcitabine Alone in Pancreatic Carcinoma
Liverpool : Novartis Investigative Site
Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients
London : Guy's and St Thomas' Hospital NHS Trust
32P BioSiliconTM in Addition to Gemcitabine in Pancreatic Cancer
London : Mount Vernon Cancer Centre
A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer
London : Guys & St Thomas Hospital
Clinical Trial Comparing Gemcitabine and Vandetanib Therapy With Gemcitabine Alone in Pancreatic Carcinoma
Manchester : The Christie Hospital
Clinical Trial Comparing Gemcitabine and Vandetanib Therapy With Gemcitabine Alone in Pancreatic Carcinoma
Middlesbrough : James Cook University Hospital
Clinical Trial Comparing Gemcitabine and Vandetanib Therapy With Gemcitabine Alone in Pancreatic Carcinoma
Nottingham : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
Nottingham : Nottingham City Hospital
Clinical Trial Comparing Gemcitabine and Vandetanib Therapy With Gemcitabine Alone in Pancreatic Carcinoma
Peterborough : Peterbrough City Hospital, Haematology/Oncology Dept,
A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer
Sheffield : Weston Park Hospital
Clinical Trial Comparing Gemcitabine and Vandetanib Therapy With Gemcitabine Alone in Pancreatic Carcinoma
Skipton : Airedale General Hospital
A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer
Southampton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
Sutton : The Royal Marsden NHS Trust
A Clinical Study of UFT/Leucovorin, Radiotherapy With or Without Cetuximab Following Induction Gemcitabine Plus Capecitabine in Patients With Locally Advanced Pancreatic Cancer (PERU)
